Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression.
Dengyang ZhangYao GuoYuming ZhaoLiuting YuZhiguang ChangHanzhong PeiJunbin HuangChun ChenHongman XueXiaojun XuYihang PanNingning LiChengming ZhuZhizhuang Joe ZhaoJian YuYun ChenPublished in: Microbial cell factories (2021)
Our data demonstrated that soluble rhFL can be produced in a bioactive form in the periplasm of recombinant E. coli. FL can be used as a specific vehicle to deliver DM1 into FLT3-expressing AML cells. FL-DM1 exhibited cytotoxicity in FLT3-expressing AML cell lines and primary AML cells. FL-DM1 may have potential clinical applications in treating patients with FLT3-positive AML.
Keyphrases
- acute myeloid leukemia
- induced apoptosis
- allogeneic hematopoietic stem cell transplantation
- cell cycle arrest
- poor prognosis
- endoplasmic reticulum stress
- escherichia coli
- tyrosine kinase
- signaling pathway
- metabolic syndrome
- oxidative stress
- cell death
- acute lymphoblastic leukemia
- risk assessment
- cell proliferation
- cell free
- big data